● Recruiting

REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)

Condition: Infertility · Sponsor: Ferring Pharmaceuticals

PhaseN/A

Planned participants500

Who can joinFemale, N/A to no upper limit

Healthy volunteersNo

About this study

This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

This description comes directly from the study's public registry record.

Talk to the study team

Global Clinical Compliance · +1 833-548-1402 (US/Canada) · DK0-Disclosure@ferring.com

Global Clinical Compliance · +1 862-286-5200 (outside US) · DK0-Disclosure@ferring.com

Always discuss trial participation with your own doctor first.

Locations (1)

Ferring Investigational Site

Omitama, Ibaraki, Japan

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06545877